Lepu Biopharma says four oncology candidates selected for 2026 ESMO Congress
AI Summary- Lepu Biopharma announced four oncology candidates were selected for the 2026 ESMO Congress.
- Four candidates’ clinical study results were selected for inclusion in the congress.
- CMG901 (AZD0901) was identified as Lepu Biopharma’s core asset with Phase III data.